References
- Ostensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H, . Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006;8:209.
- Ostensen M, Lockshin M, Doria A, Valesini G, Meroni P, Gordon C, . Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology (Oxford) 2008;47(Suppl 3):iii28–31.
- Schaefer C, Miller R. Drugs during pregnancy and lactation, 2nd ed. San Diego: Elsevier, 2007.
- Mitchell K, Kaul M, Clowse ME. The management of rheumatic diseases in pregnancy. Scand J Rheumatol 2010;39:99–108.
- Clowse MEB. The use of anti-TNFα medications for rheumatologic disease in pregnancy. Int J Women’s Health 2010;2:199–209.
- Neville CE, McNally J. Maternal exposure to leflunomide associated with blindness and cerebral palsy. Rheumatology 2007;46:1506.
- Ali YM, Kuriya B, Orozco C, Cush JJ, Keystone EC. Can tumor necrosis factor inhibitors be safely used in pregnancy? J Rheumatol 2010;37:9–17.
- Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 2009;36:635–41.
- Elliott AB, Chakravarty EF. Immunosuppressive medications during pregnancy and lactation in women with autoimmune diseases. Women’s Health 2010;6:431–40.
- Verstappen SM, King Y, Watson KD, Symmons DP, Hyrich KL. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70:823–6.
- Viktil KK, Engeland A, Furu K. Use of antirheumatic drugs in mothers and fathers before and during pregnancy: a population-based cohort study. Pharmacoepidemiol Drug Saf 2009;18:737–42.
- Furu K. Establishment of the nationwide Norwegian Prescription Database (NorPD) – new opportunities for research in pharmacoepidemiology in Norway. Norsk Epidem 2008;18:129–36.
- Irgens LM. The Medical Birth Registry of Norway. Epidemiological research and surveillance throughout 30 years. Acta Obstet Gynecol Scand 2000;79:435–9.
- European Surveillance of Congenital Anomalies, EUROCAT Guide 1.3, chapter 3.3: Coding of EUROCAT subgroups of congenital anomalies. Available from: www.eurocat-network.eu/. Accessed 16 February 2011.
- Engeland A, Bramness JG, Daltveit AK, Ronning M, Skurtveit S, Furu K. Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004–2006. Br J Clin Pharmacol 2008;65:653–60.
- WHO Collaboratoring Centre for Drug Statistics Methodology. ATC classification index with DDDs. Oslo: WHO Collaborating Centre, 2010.
- Chambers CD, Johnson DL, Robinson LK, Braddock SR, Xu R, Lopez-Jimenez J, . Birth outcomes in women who have taken leflunomide during pregnancy. Organization of Teratology Information Specialists Collaborative Research Group. Arthritis Rheum 2010;62:1494–503.
- Chambers C, Koren G, Tutuncu ZN, Johnson D, Jones KL. Are new agents used to treat rheumatoid arthritis safe to take during pregnancy? Organization of Teratology Information Specialists (OTIS) study. Can Fam Physician 2007;53:409–12.
- Osting VC, Carter JD. A safety assessment of tumor necrosis factor antagonists during pregnancy. Expert Opin Drug Saf 2010;9:421–9.
- Martinez Lopez JA, Loza E, Carmona L. Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding). Clin Exp Rheumatol 2009;27:678–84.
- Au: Ref. 21 omitted from the text.Ostensen M, Forger F. Management of RA medications in pregnant patients. Nat Rev Rheumatol 2009;5:382–90.
- Ericson A, Kallen BA. Nonsteroidal anti-inflammatory drugs in early pregnancy. Reprod Toxicol 2001;15:371–5.
- Chakravarty EF. Rheumatoid arthritis and pregnancy: where do we go from here? J Intern Med 2010;268:309–11.